Phibro Animal Health Sees 35% EPS Growth, 55% Cash Flow Surge
Phibro Animal Health’s EPS is forecast to jump 35.3% in fiscal 2026 versus an industry average of 21.7%, while year-over-year operating cash flow surged 54.8% compared to peers’ 3.1%. Analysts have raised current-year earnings estimates by 10.4% over the past month, underpinning its Growth Score B and Zacks Rank #2.
1. Earnings Growth Outlook
Phibro Animal Health projects adjusted EPS growth of 35.3% for fiscal 2026, well above the industry’s 21.7% forecast. This accelerated earnings momentum reflects strong demand for its animal health products and nutritional supplements.
2. Cash Flow Expansion
The company reported a 54.8% year-over-year increase in operating cash flow, far outpacing the industry average of 3.1%. This surge provides financial flexibility to support product development and potential M&A.
3. Upward Estimate Revisions
Over the past month, analysts have raised Phibro’s current-year earnings estimates by 10.4%, signaling growing confidence in its growth trajectory. The positive revision trend contributed to its Growth Score of B and a Zacks Rank of #2 (Buy).